<SEC-DOCUMENT>0000950170-24-029672.txt : 20240312
<SEC-HEADER>0000950170-24-029672.hdr.sgml : 20240312
<ACCEPTANCE-DATETIME>20240312083234
ACCESSION NUMBER:		0000950170-24-029672
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240312
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240312
DATE AS OF CHANGE:		20240312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inozyme Pharma, Inc.
		CENTRAL INDEX KEY:			0001693011
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				475129768
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39397
		FILM NUMBER:		24740307

	BUSINESS ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-330-4340

	MAIL ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Inozyme Pharma, LLC
		DATE OF NAME CHANGE:	20161222
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>inzy-20240312.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:inzy="http://www.inozyme.com/20240312">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_de32d52b-9853-49a4-8dfc-00bf5daa5e65" name="dei:AmendmentFlag" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301">false</ix:nonNumeric><ix:nonNumeric id="F_539c6662-430d-4c25-9a1f-7326fdd2b7b4" name="dei:EntityCentralIndexKey" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301">0001693011</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="inzy-20240312.xsd"/></ix:references><ix:resources><xbrli:context id="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-12</xbrli:startDate><xbrli:endDate>2024-03-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7253656d-d5e8-4813-9a7f-56940d26f20d" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_57fe81a7-2787-4470-86f5-a1f04e0b4481" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 12, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec5391f5-c0a2-41ae-b7e3-2e971a12ecfb" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">INOZYME PHARMA, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:18%;"/>
    <td style="width:41%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ecff7608-c46e-414a-a804-9b492d911436" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2def2fed-7a2b-4d8c-be01-261f92fe58c6" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39397</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ecd61d28-aafc-454b-b070-320ba1c7b84c" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">38-4024528</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_761f4538-c3ed-48a6-b03e-0c86f693e811" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">321 Summer Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_89973768-e40b-4854-9c09-33dc951d494f" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 400</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6f890676-c8d6-4431-b4cd-3bb6ea920b73" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_ebce5d3d-ae3a-46e0-8c1a-b71852c7b3ad" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f61d3cfe-4728-4d03-8c42-e27770b11212" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02210</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code: (</span><span><ix:nonNumeric id="F_749c6af5-95ef-4b37-b20b-2b06b4c826e5" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">) </span><span><ix:nonNumeric id="F_49caf954-4546-406a-accd-51ad4c92c5fe" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">330-4340</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_910b0933-5db8-4d84-af3a-05d6ca244853" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_035ff59c-8c62-4177-a982-99f110f20113" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f63437ec-9fa1-42b5-8486-61103741b2f1" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b09a367-1a69-4c69-8529-863b4193d938" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_de28fcb9-0497-47c9-9ff6-a092a0a31a72" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5e04ae90-85d6-468d-ada3-6bc1151922c3" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INZY</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_90acb35a-5c0a-4670-94bf-cd15282cf619" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_004e6cb4-548d-4fad-97b8-c53dc99c9a77" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_058ce08a-57c9-4a04-ba73-5951654f993b" contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 12, 2024, Inozyme Pharma, Inc. (the &#8220;Company&#8221;) announced its financial results for the year ended December 31, 2023. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following exhibit is furnished herewith:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.041%;"/>
    <td style="width:1.98%;"/>
    <td style="width:90.978%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.75pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exhibit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.75pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.75pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inzy-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release issued by the Company on March 12, 2024</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;"/>
    <td style="width:44%;"/>
    <td style="width:4%;"/>
    <td style="width:46%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">INOZYME PHARMA, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 12, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Douglas A. Treco</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: Douglas A. Treco<br/>Title: Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>inzy-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2013; Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2013; Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients receiving hemodialysis (SEAPORT-1) now underway (NCT06283589), with topline data expected in Q4 2024 &#x2013;<br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2013; Launched global patient registry (PROPEL) in partnership with GACI Global to advance understanding of ENPP1 Deficiency and infantile-onset ABCC6 Deficiency (NCT06302439)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2013; Cash, cash equivalents, and short-term investments as of December 31, 2023 expected to fund operations into the fourth quarter of 2025 &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">BOSTON, Mar. 12, 2024 (GLOBE NEWSWIRE) -- -- </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Inozyme Pharma, Inc.</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (Nasdaq: INZY) (&#x201c;the Company&#x201d; or &#x201c;Inozyme&#x201d;), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the full year ended December 31, 2023, and provided recent business highlights.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We believe we are well-positioned to continue to advance INZ-701 through several anticipated value-creating milestones in the year ahead,&#x201d; said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma. &#x201c;Of note, we are on track to report topline data from our ongoing Phase 1/2 trials in adult patients with ABCC6 Deficiency and ENPP1 Deficiency in early April. Data from these trials along with learnings from our recently launched global patient registry in partnership with GACI Global have the potential to play a meaningful role in bringing INZ-701 closer to patients facing these challenging diseases.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Dr. Treco added, &#x201c;Beyond our two lead indications, today we are pleased to announce the initiation of our Phase 1 SEAPORT-1 trial in patients with end-stage kidney disease (ESKD) receiving hemodialysis, of which calciphylaxis is a severe complication. Calciphylaxis represents a devastating condition characterized by pathologic mineralization and intimal proliferation. Clinical data to date have demonstrated that INZ-701 was generally safe and well tolerated and meaningfully increased PPi levels in adults with ENPP1 and ABCC6 Deficiencies, conditions that share similar pathology to calciphylaxis, supporting the idea that INZ-701 could ultimately serve as a therapeutic option for this underserved population.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Recent Updates and Anticipated Milestones</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Phase 1/2 Clinical Trials of INZ-701 in Adults with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE) and ENPP1 Deficiency. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company expects to report topline data from its ongoing Phase 1/2 trial of INZ-701 in adults with ABCC6 Deficiency and topline data from the first three cohorts of its ongoing Phase 1/2 trial in adults with ENPP1 Deficiency in early April.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Global ENPP1 Deficiency and Infantile-Onset ABCC6 Deficiency Patient Registry (PROPEL NCT06302439).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> The Company announced the launch of a global patient registry in partnership with </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">GACI Global</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, a patient advocacy group that connects families affected by generalized arterial calcification of infancy (GACI) or autosomal recessive hypophosphatemic rickets type 2 (ARHR2). The patient registry is designed to better characterize the natural history, disease course, long-term outcomes, and true disease burden in patients with ENPP1 Deficiency and infantile-onset ABCC6 Deficiency (GACI Type 2). The registry will assess three distinct cohorts: </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Patients of all ages with ENPP1 Deficiency with evidence of biallelic ENPP1 variants</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Patients with evidence of monoallelic ENPP1 variants and disease-related symptoms</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Patients under 18 years of age with infantile-onset ABCC6 Deficiency with monoallelic or biallelic ABCC6 variants</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">To date, the Company has identified over 1,000 patients globally with confirmed or suspected ENPP1 Deficiency and collected data on a number of symptomatic ENPP1 Deficiency patients with monoallelic </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">ENPP1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> mutations.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;At GACI Global, we are dedicated to furthering the understanding of these devastating diseases in order to advance the development of potential treatments,&#x201d; said Christine O&#x2019;Brien, co-president of GACI Global. &#x201c;Our partnership with Inozyme has played an important role in that mission while ensuring the GACI community has a voice.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Phase 1 SEAPORT-1 Trial of INZ-701 in Patients with ESKD Receiving Hemodialysis Now Underway (NCT06283589). </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company today announced the initiation of its Phase 1 SEAPORT-1 trial of INZ-701 in patients with ESKD receiving hemodialysis, of which calciphylaxis is a severe complication. The trial is designed to assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of INZ-701 in up to 10 patients with ESKD receiving hemodialysis. Patients will receive 1.8 mg/kg of INZ-701 once weekly, coinciding with their hemodialysis treatment, for a total of 30 days. The study&#x2019;s primary endpoint will assess safety and change from baseline plasma PPi concentration, with secondary endpoints including PK and PD parameters. Topline data from the study are expected in the fourth quarter of 2024.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Inozyme previously presented data at the American Society of Nephrology (ASN) Kidney Week 2023 in October 2023 and at the European Calcified Tissue Society Congress (ECTS) in May 2022, which showed the following:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Patients with ESKD had significantly lower PPi levels compared to healthy subjects</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Patients with patients with calciphylaxis had significantly lower PPi levels when compared with ESKD patients without calciphylaxis</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Low PPi levels were associated with morbidity and predicted 6-month mortality among ESKD patients with calciphylaxis</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Low PPi levels are correlated with higher numbers of skin lesions in calciphylaxis</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;ESKD patients suffering from calciphylaxis face a poor quality of life and, unfortunately, a particularly dismal prognosis,&#x201d; said Sagar Nigwekar, M.D., MMSc, Co-Director, Kidney Research Center, Massachusetts General Hospital. &#x201c;I am hopeful that INZ-701 could serve as a much-needed treatment for this underserved patient population. I look forward to the data from this study, as well as more advanced clinical trials of INZ-701 in calciphylaxis.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Anticipated Milestones</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ENPP1 Deficiency</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Topline data from first three cohorts of ongoing Phase 1/2 trial in adults through 48 weeks &#x2013; Early April 2024</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Initiation of the ENERGY-2 pivotal trial in infants, Ex-U.S. &#x2013; 2H 2024</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Interim data from the ENERGY-1 Phase 1b trial in infants &#x2013; 2H 2024</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Topline data from the ENERGY-3 pivotal trial in pediatric patients &#x2013; Mid-2025</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ABCC6 Deficiency</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Topline data from ongoing Phase 1/2 trial in adults through 48 weeks &#x2013; Early April 2024</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Initiation of Phase 3 clinical trial, subject to regulatory review and sufficient funding &#x2013; Q1 2025</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Calciphylaxis</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Interim data from SEAPORT-1 Phase 1 trial in patients with ESKD receiving hemodialysis &#x2013; Q4 2024</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Financial Results for the Year Ended December 31, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash Position and Financial Guidance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; Cash, cash equivalents, and short-term investments were $188.6 million as of December 31, 2023. Based on its current plans, the Company anticipates its cash, cash equivalents, and short-term investments as of December 31, 2023, will enable the Company to fund cash flow requirements into the fourth quarter of 2025.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and Development (R&amp;D) Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; R&amp;D expenses were $54.8 million for the year ended December 31, 2023, compared to $47.8 million for the year ended December 31, 2022. This increase was primarily due to an increase in chemistry, manufacturing, and controls expense to support our ongoing clinical trials and prepare for potential commercialization and personnel-related costs.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">General and Administrative (G&amp;A) Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; G&amp;A expenses were $20.8 million for the year ended December 31, 2023, compared to $20.8 million for the year ended December 31, 2022. The expenses were flat year over year. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Net Loss</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; Net loss was $71.2 million, or $1.37 loss per share, for the year ended December 31, 2023, compared to $67.1 million, or $1.78 loss per share, for the year ended December 31, 2022.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About ENPP1 Deficiency</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ENPP1 Deficiency is a progressively debilitating condition of the vasculature, soft tissue, and skeleton with a prevalence of approximately 1 in 64,000 pregnancies worldwide. Although ENPP1 Deficiency was initially described in patients with biallelic ENPP1 Deficiency (homozygous or compound heterozygous mutations), many patients with monoallelic ENPP1 Deficiency (heterozygous mutations) have clinical symptoms, potentially increasing the worldwide prevalence. Individuals who present in utero or in infancy are typically diagnosed with generalized arterial calcification of infancy (GACI Type 1) and approximately 50% of infants die within six months of birth. Children with ENPP1 Deficiency typically develop rickets, a condition diagnosed as autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while adolescents and adults can develop osteomalacia (softened bones). ARHR2 and osteomalacia lead to pain and mobility issues. Patients can also exhibit signs and symptoms of hearing loss, arterial and joint calcification, and cardiovascular complications. There are no approved therapies for ENPP1 Deficiency.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About ABCC6 Deficiency</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ABCC6 Deficiency is a progressively debilitating condition of the vasculature and soft tissue that is estimated to affect approximately 1 in 25,000 to 1 in 50,000 individuals worldwide. Infants with ABCC6 Deficiency are diagnosed with generalized arterial calcification of infancy (GACI Type 2), a condition that resembles GACI Type 1, the infant form of ENPP1 Deficiency. Pediatric patients who survive the first year of life may develop neurological disease, including stroke, and cardiovascular disease secondary to ongoing vascular calcification and stenosis. In older individuals, ABCC6 Deficiency presents as pseudoxanthoma elasticum (PXE), which is characterized by pathologic mineralization in blood vessels and soft tissues clinically affecting the skin, eyes, and vascular system. There are no approved therapies for ABCC6 Deficiency.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Calciphylaxis</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Calciphylaxis is a rare disorder with a high mortality rate that mostly affects patients with end-stage kidney disease (ESKD). The disease is associated with low levels of pyrophosphate (PPi) and is characterized by pathologic mineralization (i.e. calcification) and intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels) of the vasculature in the skin and fatty tissue leading to poor blood flow, blood clots, painful skin ulcers, serious infections, and death. Patients with calciphylaxis have a reported one-year survival rate of approximately 50%. The estimated incidence of calciphylaxis is approximately 3.5 per 1,000 patients with ESKD with approximately 5,000 new patients presenting annually across major geographies. There are no approved therapies for calciphylaxis.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About INZ-701</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">INZ-701, a recombinant Fc fusion protein, is an ENPP1 enzyme replacement therapy (ERT) in development for the treatment of rare disorders of the vasculature, soft tissue, and skeleton. INZ-701 metabolizes ATP to generate PPi, a natural inhibitor of mineralization, and AMP, which can be processed to phosphate and adenosine, the latter being a natural inhibitor of intimal proliferation. In preclinical studies, the experimental therapy has shown potential to prevent pathologic mineralization and intimal proliferation, which can drive morbidity and mortality in devastating disorders such as ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis. Clinical data to date have demonstrated that INZ-701 was generally safe and well tolerated and meaningfully increased PPi levels in multiple clinical trials.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About GACI Global</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>GACI Global is a nonprofit organization whose mission is to connect families affected by generalized arterial calcification of infancy or hypophosphatemic rickets to each other and to the medical community. The organization strives to provide current educational resources and supports ongoing research.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">https://gaciglobal.org</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Inozyme Pharma</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Inozyme is developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation, which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">https://www.inozyme.com/</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> or follow Inozyme on </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">X (formerly Twitter)</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, and </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Facebook</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#34;forward- looking statements&#34; within the meaning of The Private Securities Litigation Reform Act of 1995.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">These statements include, but are not limited to, statements relating to the timing and design of our planned clinical trials, the availability of data from clinical trials, the potential benefits of INZ-701, the expectations for the global patient registry and the sufficiency of the Company's cash resources. The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;will,&#34; &#34;would,&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's ability to conduct its ongoing clinical trials of INZ-701 for ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis; </font><font style="color:#333333;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">enroll patients in ongoing and planned trials; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain, and protect intellectual property rights related to its product candidates; manage expenses; comply with the covenants under its outstanding loan agreement; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the &#34;Risk Factors&#34; section in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Consolidated Balance Sheet Data</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:69%;"></td>
    <td style="width:1%;"></td>
    <td style="width:13.84%;"></td>
    <td style="width:1.2%;"></td>
    <td style="width:1%;"></td>
    <td style="width:13.96%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">December 31,<br>2023</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">December 31,<br>2022</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash, cash equivalents, and short-term investments</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">188,589</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">127,866</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total assets</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">200,847</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">139,195</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">60,368</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">20,801</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Additional paid-in-capital</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">426,362</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">333,356</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Accumulated deficit</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(285,930)</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(214,761)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total stockholders' equity</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">140,479</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">118,394</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:67.88%;"></td>
    <td style="width:1%;"></td>
    <td style="width:2%;"></td>
    <td style="width:13.12%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.72%;"></td>
    <td style="width:13.28%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Year Ended December 31,</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2023</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">2022</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and development</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">54,847</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">47,849</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">General and administrative</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">20,798</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">20,826</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">75,645</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">68,675</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(75,645)</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(68,675)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other income (expense):</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest income</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">7,837</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">2,195</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Interest expense</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(3,333)</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(262)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other expense, net</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(28)</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(319)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other income, net</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">4,476</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">1,614</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(71,169)</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(67,061)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Other comprehensive income (loss):</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:20.15pt;vertical-align:top;"><p style="margin-left:20.15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Unrealized gains (losses) on available-for-sale securities</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">264</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(198)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="text-indent:20pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Foreign currency translation adjustment</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(18)</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(25)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Total other comprehensive income (loss)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">246</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(223)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;min-width:fit-content;">Comprehensive loss</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(70,923)</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(67,284)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss attributable to common stockholders&#x2014;basic and diluted</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(71,169)</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(67,061)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss per share attributable to common stockholders&#x2014;basic and diluted</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(1.37)</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">(1.78)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">Weighted-average common shares outstanding&#x2014;basic and diluted</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">51,839,131</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.1in;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">37,763,168</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Contacts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investors:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Inozyme Pharma</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Stefan Riley, Director of IR and Corporate Communications</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">(857) 330-8871</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">stefan.riley@inozyme.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Media:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SmithSolve</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Matt Pera</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">(973) 886-9150</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">matt.pera@smithsolve.com</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>inzy-20240312.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-12T07:42:27.9486+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.inozyme.com/20240312" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:inzy="http://www.inozyme.com/20240312" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="inzy-20240312.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>4
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140001517500320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 12,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOZYME PHARMA, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001693011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-4024528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Summer Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">330-4340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INZY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>6
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MR,W \9W]A6>Q6AM[P1WV<[;B,V[^R*<*SMQ*)18IS[20&5%\.7!"_^:6=NV
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  01&Q899!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ $$1L6)E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  01&Q8:>0!(H4$  #+$0  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ $$1L6)^@&_"Q @
MX@P   T              ( !R P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  01&Q8EXJ[',     3 @  "P              @ &D#P  7W)E;',O+G)E
M;'-02P$"% ,4    "  01&Q8.JJBYT !   \ @  #P              @ &-
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ $$1L6"0>FZ*M    ^ $
M !H              ( !^A$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ $$1L6&60>9(9 0  SP,  !,              ( !WQ(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  *10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="inzy-20240312.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="inzy-20240312.htm">inzy-20240312.htm</File>
    <File>inzy-20240312.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "inzy-20240312.htm": {
   "nsprefix": "inzy",
   "nsuri": "http://www.inozyme.com/20240312",
   "dts": {
    "inline": {
     "local": [
      "inzy-20240312.htm"
     ]
    },
    "schema": {
     "local": [
      "inzy-20240312.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20240312.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inzy-20240312.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.inozyme.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0000950170-24-029672-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-029672-xbrl.zip
M4$L#!!0    ( !!$;%A.6"7.DA(  #&=   1    :6YZ>2TR,#(T,#,Q,BYH
M=&WM/6U3XSC2W_=7Z)B[7:8*)7Y_"0Q7;(:9S;,S0 %;M[=?MF1))KYQ[*SM
M0+*__NF6[9"$A-=D"!"J9B!16U*W^ETM>>_?PUY,+F661VGRX2>]H?U$9,)3
M$247'WXZ.&MW.C_]>_^'O6X!8 ":Y!^VND71;S6;5U=7C2NSD6873=WW_>80
M8;9*H-8PR&(1C6'QHX(T-,UIEHU3H,5<4+L$+29!HZD)3$*;S2C)"Y9P6</'
M4?+M%G!L#E@^!A_>@)_"#UMKT&BXJ%\=IP&@\O>?3[_4X$F:' UZ,HOX_,=$
MD36+45\V 9 F)>1X5GDT;TZ @=[\_>N7,]Z5/49G41=RAOJYY(V+]+()#?"L
M85YC4E!HFQJBAKU&I%ED+,G#-.NQ C@%\;2IYE%3G^AG/FZW=6(85#.H[HP[
M2?X>3?42)>G?HYYL\+2'X)9FZL;6_@]DKRN9@-]DKXB*6.Y[]->]9ODG?MF3
M!2/8#95_#:++#UOM-"ED4M!S(/(6X>6G#UN%'!9-Q;=-[+19];H7I&)$\F(4
MRP];/99=1$F+L$&1_B/J]=,,"%WL]IE (6D1KS_<W5*CBNBR?DA$>3]F(UQX
M":U[T;"%?<NL_#,20B;JSVO.()'XL/7I3R%-0]A&0'W/-JGE,XMZ(N14TX+0
M%HS9TK&W2,)Z.(J,6@<]F0CX5WR*V46%VK XE2$@_:<K+6%H(:.Z;G)J,>%3
MY@B3ZE+W TL/35/3M_9#%N=RKSDUF_F3LTV?.XYC4,O4!+6X85.?Z2%U3<,)
MA3 "-[ F)W>8P)J,VC"[C,6=1,CAKW+TN$EJP.^.#W_J-V;:G"9I)D.9@1*3
M^?X>RFPK5R("HQ$EPRV4M ];.:QEC/*BONMF.!GD/UKS66.8"^ +U?UDG^IC
MG@XR]4GII%:%D2+3?3&J'I6*1O6G2.#G,)(94=.6<P6SW?EUFB*S#^_77TWW
MW@>"I:+^!!HC*SZR0NXCRE2#"1KU<]=MXVF*!:!U2_VY'J0Y19J:CF/"-2=D
MH@FB,RM"O2BA71E==(N6UK"C!,5H#->OH8(T@QYHD?9;1L.P^P41Z2"()7FG
MJ9_=$(:G>?2W;.E:O]@MI5G!5VTAZT7QJ'4>]61.CN05.4U[+*D!@[0HTA[
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MA20'O,!FW3>M&0H6#%VU:5<.<<' "I@"6RF$4>F@@-D,I=@M9Z9K6@-DHGH
M"!*S?BY;N>RS##S1,AR#WK.ZZ\LHCX(H!D^X54-70  EQD)4=_ZO714/0B.$
MK+-]53ZI6NFYU+^":=$@D^Q;2_U/\8LY CP[?!51E@JEH>G@\E[*K(@XBZL'
MH06YX1Y\]S"%-*5M8&C#]QQ]X@=FLA*V7,1K&$X@QYQ*C+;)=OU9,@@H9%X0
M>0F )%/-4KQO31G*!:&K&TI/9RXU7,^EEN5JU'-"FT+XJEE2"RRP@\LR>B<J
M CHLXZ(M4F8\(+H<%BT!W] >C-+%QZA@(SH"M*A,5DC/KRSC7:(;.P2CM[NM
M(+"]F.)_^(VR^%CS^-!(Y T8R-<=?"[;^E\/95B/\WDEMTU?!WGG&C.HI3-)
M U>:U)"^JS/=D#P,GBK^9;;K5%Y$.68ZBR-H6:KQOA/Y10O9.3K^X[]?#\G)
M+P>G7P]V2.>HW7B@,[QXM<WU\O7<QIWLMX!*VX=#!JX*+FAI?>J%)"PG9WW)
M,;4F2)203I&3=I>!\<G>/SUZ>*BSO%&/:ZP>U]&E-:X]VCG^[BUMMS_HW=)H
MZ=_9B08BX#I\V#*WGM^A7JCB%AFG,'0=S:/<<B08)XM1YFD6!2OC&\+7=<MT
MEF.<.@E/,_":U0;<60&<U4X'29&-VJF8]E1Q4Q!W 0K9S])+[&>E+NI'&;,K
MELD'.*?K$3L]<*D-(4,CE(*ZS BH)3Q. ZGIU'#TT(<&V^-+6NI/42QA[$!F
M*UPV#:9N^J;OOO9UDUPXNC \RE@(:V!; 0TTB"%-0PN8SMW L_ARUNV<#3O5
M/AY78KKR130]:D%<:!O>(T+#.5K=75>E7KJ&RV>952S*MM+.F%\[+KHR(_\W
MR*)<1"KQIG:WP$.=TN;O5REK+XIR[;37BW*L:"*H!$DI0!OZU/3IG)Z1PUX_
M3D<R4ZPTK6_(4=J82ZQY(O]*,J!W+L!</.\=&+P4V[?!=H/M!MN'>3N;&+8L
M*H  QK+!E>0F1#>6QQQPD$U)->XYH>.;TM.?O+]2.L@'0F0RSZM?7Z)$ZJMT
MC@V=G UZ@"HY*S(IBWOXR,^]%I[ONZ;K>%1:&@29GFU1GVL^-4W!?5L7EF^%
MJUH+8X5K<3: IXFE:0^--L>"9:RS8*VOSEJ&CIJ3I'UN.7%"S]<<UZ'<$PZU
M+%.G@<4%-8/ D<R'T-XUERHG;?CS.#M/KU:92OLYS0N($6\7D54-OG./K7@9
M<&D+4U F348M1VK4XSJC@:M[ML'=P&1/KC^;(KL*I8^SDRR]C-09B>?+<WYE
M><YX=Y#+HLA?<M+LWALMJW8MR\FMHWH)'5V8/)34<@V/6D(S@<\M@TK#=5TM
MT'5#-Y;*YR<@^2S^(^JK;/X*L[Z&H3_$!F]RA2O.Z%3KC[O6)QFHN*C/8G(X
ME'Q01)>2'(=AQ&6^T@S8R_")WF2^#Q0"08UP:U)O;HG79H/^3=6<ZH;]=HM.
MK\M]?GSG&;J[FY-S&<M^-TWJ+80=W'&)!T@Q<@!D5E+5(MMWN[RNY7.'A3;U
M;1E2*S!=&D!X08U <R#D\ Q'VD]U!3"XP%FMV/A[]EV;O0\<>=% [^\12@!9
M6>C;%N[(0@2G.8PR#A&<K3-A<=_@=BB?2M<O*0C#";+!ZG=B38U:IO48WVJC
MO]=8?[\6G?V]4U??BZG7K [U4YIAOOE(%:)FI/I8.?D[) JQ^#2YD(*<83Z#
M?&%Y41V66$8Y:L/<%.P_G2HSA[GFX7A?!GL:QNVNY-_4X2S6[V=I/XNPL"1(
MAR20<7J%[(2-R&7$H[^2$)0>.#A13B+L0@";%2G)H]X@+E@BTT$>CTC.BB@/
M1^K)ZH$T $3+"H+J,%AV74$]@'XRPI)1W1:"3DVO\#G,NT58K9&WGI*=?!J1
MR Q'3%Q$H!8Q2K!&HD4-2XEUK8.5.%7?S51T/]"&3LF'+GN[-[Y8>";B3J07
MG(GP=2W0?-.DM@@P/^59E(4FHYHM',X,R_+L)Z>__Y-%!9 82W(&255@DM],
MP 9I&@<,.*( OGP*HC^^\UW+VKW+@7HN-JO( 42=I ?I3QRN/!V >V,9=B4R
M,X<J\2SEMNZ2]J=38IA: P"O5?Z<6S0>P;S.BV!>S;3#T/8Y]3C>1Z.[+F6^
M9U#?#W5="PT-&/2IS'L&%HP#W9.+KZ R06_&;Y=SKVE!>A4Q;K(M5J[KQ@3G
M3IT!'O.M!6ZK@GR;K!LZIF6ZDE,_9#JUC,"FGN4YU '&-5U+#XSPR:42)YE$
MG8M7%JEK&-".9\=A".'KFV5AH GE$T2Y4POKEJ#&=O#^?@Q=PKY-EC;!D6"F
MXU*=.3ZU./SGV0;\YYC G;XI?--;,DMW\GP@LPUC/XJQ34FM;7X_QJY@;S+V
MTN^_\+_#_1>/MG_7/E@9UL@, J/^O%LQE,JHPAR@9NL%)+#,V\[RW79"4+<?
M^:!EKV+'X[$UY;,)#&.<P'C>PH)5))E5R?\YWI59WJG!NX3'+,^7LU^ZF)+D
M7:A^-//-U*:\-=8ZSQA2I+RD;]0#V.UE51UL^.H-\Y5BJ*/J7@:EL63MKH#!
MA;[AFVNK_/V*85]Z :R0AA?RP*>:Y;O4<KD/,6GH4*;Y!M.8J3/WR15JE>,T
MTHU &9V'L\G"Q#9XN2EVE/)O.P3<('+)XH$D_X0UT#2=]/$2W>X+/U2^5CIG
M#5G8EIK%I*]!O(DUW(XG*!/,I$[ ==W6?</@3\X#5F:MM&C+X]_.T1__W;#F
MZV5-7V,\,&U&;:YAG;NK4=\*0LJ%;AN>P4-']Y>E7>OP7=TY=2,1@M;RL:7M
MBQ;OB.6"_44^QVG 8@A^8PA_R5>6?;O7$:DG[O3??8WEP]CV^^1I.HG G(PD
MP8APM2L+T_P&_HM41_QGMDRCG, $)=#N K/N%UEZ570QM=/';526$R'#*"DO
MI"HWC31[SC6<U[=OFF0;)<[=Q0(WT]]5^T?U,S :<% ?;[3"FH,R360$U+CG
MS9ZS?6/FZ/KQB=X;Z[/)N]J+;)^/SPX7\,P=UTGC<(MVVS1+.CRPJ&V!@;5"
M)JCO!A[E-AXI]+G/7'<Y1QGJN7]64V^7,U]U:M>Y,[7[NAFF$]ZB:G9 P<S5
M6]&-*H\N:"5E"$ K):G*B@YRJ:  S:J6!%\"$ZE,:?FF"%Q;-58\PL&O(A@:
MN36!:4-+)B^C')X#7<<2CMN.C'.\M J!\:4W@F4B+ZM(Q**4K+G-QBG92>W5
M>(I,V!Z7F@?F'>,FBVD6#9AK4MNW=<>V0M\WEW2EY.'P?$RT\F[9Y]_K6-%5
M?M-9C?FO]%BGRK&)S;TPED,JHJSD.<RY#WK);OTF(&S=O?%.D_\-\B(*1_4H
M"HJ"G"!.XWV6;G;M"E_(,B%!60C&M,7B*S;*JT3ZP]^><HN#=><U^ZLJ=EOR
MODVGD#UB-#2#G,I\$!?JD-0Q:)YJ;PST!_DT5BWM%%0=-C16S>AKH?>/$_38
M)^Z&QA,.ZHU;Y*3+0,&H$P\-LHUZ$ST[0]NM3++ZI.^^!P(FH(TY^J% W&LM
MG57D1NV.C^,UUZ0T 1\EEUA)3TQ=#6LVR#F6! [BF*C7*%6:NJ\.M65@41A8
MD0@W?)6W"P@DE697UD+5-E;34/N?X&X&$NU#.,B2*._"8PS=UFX41 7Q_8:.
MUD&YI>U!EN$CU5WC>&=470B)K*&J(.M;MJ ;\-.A8S2$XU="O0U6(8]PGE\@
MFLB'43)^1QURFV*3L1I!;Z@^ S3%4*PH&.]6+%*D.YAZ!'Y&-RB0$*L!9XI:
MAL(HEJ*2("4@X+3TTUPJY31V6KQ[AEX[R-RL5\K6I*A. M?RNH,^58KQYA6X
M520?!/_#P%V)@R1QQ-26<51.I>BR@N3E?'8 E:Q"*IK$:4H^)@4#B8>.7%4?
MW&-">9 X3J5$%M<X5A'K)&IJYK,.W [N!,B^NJ)9#I7"P.ID62!9037 >'EY
M<S.?GE@^ +7'JKD]0H1?EX'T&YH^80;5A0FH24O[6/%Y_C8T';[-I,9XMG;C
M=6)\/E6/+RNM!EKOVGRB4D-;^]P$>;ZC9I,':/!=H+O+*]V9JL]3?3^IF,=M
M:-:M-3L-_[9R'U]K^*ZWSM4Y<XX7U1V-CQ//G!]>ZWWPA7F\4A)74R]P7R(^
MPR;2$TA&GI=8+YWC/LJ<9U%?73*\GE44&Q[=4.*M4&(C;LL@+4;GW^MVSB5/
M7=>LC82\'EW!R,1KYN70]__4&]VBMYA&83B?1JIO(7EU]7]+I5'B*)&W'1')
M<W(ZG4J=2<:DL]G@,<79BY.<=@IK3T[8A20=])$85S>A?60%*U\*L(T9:($9
M,PQK59H/09&(Y/>?3[\04;W,<7-KUFO>YWK(BE170*SM":7.YZ.#\]].#\]6
MFZ.Y28;GRUQ-OI6XK$7X:P"<6:8N[YL]GU/$( ;QB' VP,(#E?\OWS6+PP22
MY( T-.#V0($[35T6A[4R5:JX L LNQPD\)#JCPV*;IH!OF(VD;J.1\*<VPYO
M6;<UWM;FK%->Z2W5QVYP?<NX6HV'O:6UA%^=>W;K"VF7]\JAC6+8X+K!]:7A
M^F(\@X=JU54&O!#9RM8ZFY15(K\@;?'&J/#SZ+$7Z'WGW;2)H\HOC\K-O$D^
MIH.+&,+$@P8YSR1/7[066T<3L,%U@^N#<&VX#[MI:%DYK,6G(WNR=5-/C*]>
M:9%V-Y+AC9=T9)ML\WIEF_>:02I&^S_L-;M%+][_?U!+ P04    "  01&Q8
M43$Y^KD(  #89   $0   &EN>GDM,C R-# S,3(N>'-D[5Q;<]HX&'WOK]#2
MEW:VQL9)+V%*.FS2[#";)IF0SG9V9Z=C;$$T-1(KVPGTUZ]D6[[*AD!L TM>
M8NQ/1^=8]X/$QT_SJ0T>('40P;U6IZVU ,0FL1">]%I?ATI_>#88M#Z=OOCX
MBZ* \XO!%;B"CZ!ONN@!GB/'M(GC40A>#;^\!M]^N[T$0_,>3@UP3DQO"K$+
M%'#ONK.NJCX^/K:M,<(.L3V79>>T33)5@:*$X&<4&OP^.#=<"+JZIA\KVI'2
MT>^T]]UCO:N_;Y\<?WCWJZ9U-2V1C,P6%$WN7?#*? UX*I8WQM"V%^ "80.;
MR+#!4&3Z!@RPV09]VP:W/)4#;J$#Z0.TV@'FW+&Z3J#!->@$NE?&%#HSPX2]
M5D()PN3G8@I]#3Q3[:BCMX#ANA2-/!=>$#H]AV/#L]U>R\/_>H:-Q@A:[/7:
MD+^75$#B,2L/['0A]J9ZE-]\1.TVH1.>D:;"N0NQ@T8V5'@8I/Y;<Q2=%UZ0
M'.&?BQ78!L%,<"KV\2C,2^NHW[Y<!N4I@FV$?Z2B$]RT(Y4_'AD.%.&>HTP,
M8Q:E&!O.R(\.'W R1R+8@B@MV8%F>T(>5/8@%<@?6J[L]6AOU>!A,A25$&;5
MT655)"(\SPD,7T?GY.1$]9^V3E\ X%<3-)T1ZH*@MEP2TR^(DLSX)T7DJ/!;
MK'8K1YTV VL!+*UG!735S4B(<EJ+1%3(ZY(0A<1S?UN4K[145\K1*:H__$+A
M%Z5YYFK=TS*55G$5VJXC[I12D+>0F(*!,7']?/DM<7,V0WA,@COL'B^A+B4V
MO%O,(. 77V\'2SL$U37F!)/I0N4I5-&#B_]];'W&+G(7 Y85G?H<6@"QSN.6
MA7]?*5PP%!PMR 8$Y*OI:/R/#1>)D2.Z9& @0 ,)N(]J%B0#[SG0NL:G_O6,
MLGX>!Z_NDMT($X<A)0E-PS8]^^GI8EJ%R<*;HJ32Y2>:F?^*[;#?R1;P+1Q7
M6[Y^E]>]IW#<:_%A11%HO *_7+WD0R"7R>RU'-:0[+#_2$DV1M#F;RN,YCQ+
M.B)?AM\E"W3D\@013#I7?^"TV" ;9QME3,Q4J,W;-J%I^:OW+2_9A^]GA,VK
M^B/'I8;I"B2?6J^5?Z[60ZK/"LCRYQ^V,9&02C^OB=09JRM]-OL[(Q:4O:CD
MXYHHB;I\ RDBK#I;?%(JX2:/JYDD[SM*N/F/:Z(4-/R^9;'>U@G_L98(.Q)^
MQ;$-D]6?0%9OA"QO$M?TCCSB9503D4T0O2%LPFK_A68%;;LDN FZ0S8_@-?T
MAI('%*P*2@EGPVNE?,::-C7L 1O2YG_ 12'7;%RM)#^S]>D$X<GOE#RZ]V=D
M.C-P,55Y=+V$YW?48,MK/FD).O5BMOG06JE>(!M>>=,1I(44$R&U4AM@DU"V
M5O+G?GXK.2,>JX:+TFZ@/%6M F[A!/&9&?;MGT+&F;!:*=X9\X'%VC8:HV A
MNJ0N%,771)HOE^V;>X*+ZVPNI"9J-Y15M"F;*IF^-3=P' _2.[Y6H-?CL93J
MTB3-4'\2Z0;H#J'I4587._KHCJ_5)"1S(353^SPW[PT\@07M7AI6%T5B(Y,-
M-WCRA?6-%!FVC& ^J"9Z;#3DWQL,%],1D3%+/Z^)U)^LL-BRG]=[#X<=GR,A
M)X^3D>1IN%O,KOB7)! K7X=IHX%-#8E'I=/'U*+_NSV*WM-*5@?':9WZ&.!O
M@?)/Z"+Y3Y^;;\H/6)-OA $X2)5LDT[!NB^7>XP< W"0*LE*K8,U64=&:0 &
M&)K_-5H=_+F]L"EMCE$EUT*K84WBH1<=(KT1%X!C@FO<B!:]"BUWCZ0V+;%5
M\4Q*_+9,*."0M:E(F1C/)"3 ! RT\EZIS-]X)C4^*B\7@5N]GHP'LIF0$ SX
M:(#!5<]?:HQLID) @@ 3A* U:,G9)AL*F8,8,!P JU<1.RN;L><X( "JGG2I
MP;*9CA1THHV'&=34;Z7]F,T4Q5B @U5/OL"@V4P% P5IU!IJ6];(65."#P-\
MG!I(+[-TUA3!8!4S@0L"8! @ Q^Z1ED5"*I+2=896I._GQ:0,>CHKT:O@4"M
M@WG2-%J3O8 " JORSBEO**U+/0(" JE*WBF[:=VZ$F"  *1*ME+_:4W6(19(
M@ZW OD_3!IQ!39$]NUS"((Q03<(ZAIFK!&3"Y&-*IK)M+R([4F2/%3EP=5"5
M;I815//.6)-495MHHI>:=<6:)%JZL48P+K;&MH%Z<KM-EG%DAC5)=.DF',&Z
MW!;;1@GZJA+T[9*0W[ C%9"QP+:&OG0;CU1!WO[:&A$%FWND,F3.5_-""K;\
MI!7(O*[FJ9=N!$H+*#:[MD!&X?:@C :YR=6\@/RFH33QC*_5/.&5MA*E-2RW
MN9J7)=]@E-8A<;.:)[YDVU%:09FEU:24HLU(@KW4P&J2\*I;E(2 E<RL+1*T
MNI1M$E&TG4E0ESI6VT!8MLDI2SIG5C5*O'#K4T1;;E,U25JZ(4KPS=M335(M
MW28E*!=[5,F37 F;B2W$?F3/>&7/X1796\]\@BT\&I;-/>W/'4Z('4Z('4Z(
M54OI<$*L%K*'$V*'$V*'$V*5$#Z<$'L&:H<38H<38H<38O53/YP0VYC:X838
MNO3^'R?$DA[#LW@W,X,R/,6\1W8TUUAQ0TUF-4\H:\^]5D?3.AK_N;@9FY/P
MNMIKL16-YS R9,9IRZO$-@E+.P*1KL[1CNLJL!7B@M/W1&!@2<2ZM!W75>)K
MQ")/]E2DGA+9V2.121\E[F7VJK)F')A8Y:YW->7&3:QSU\?" K<G;I''>R&P
MP"F*9;[=#YD2?RG2J.]'SY,TIN+R>[<7VI8X6['<]WLA-^N#Q?IV?2J^Q$2+
MA7[8<:%YXRT>&W=]Z%CNW,5:=WUV7F;UQ2IWO;;F'<)X=-SUF9S<8HST'>UZ
M:Y3YDW'-W/4!,6-OQM5RUQ=2!19I7')/F;F%&\2R.[%$@-@_AH)?/P]N?U0S
M/W,?WDC\&'YP)_AI_M/_ %!+ P04    "  01&Q8;W$<UG<C   2RP$ #P
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M/,T3W=$BE6,Z_)4,LO!@++..#X^+!#=R<AW*D<R8N0=<YN?7KZ;/ (3EQWZ
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M;RY.?@.9Z@RM*X&*1TBA>5CXMO<NE,S+K9&2 V#Z0Y4$4<-:PNY @LJ$(O(
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M?")F<F"LRQ^F#CZ\]!@5R^-#='M==I3<]C+:X*CHD0>4#$HE?O!3U2RO@6N
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M<?3S_P-02P$"% ,4    "  01&Q83E@ESI(2   QG0  $0
M@ $     :6YZ>2TR,#(T,#,Q,BYH=&U02P$"% ,4    "  01&Q843$Y^KD(
M  #89   $0              @ '!$@  :6YZ>2TR,#(T,#,Q,BYX<V102P$"
M% ,4    "  01&Q8;W$<UG<C   2RP$ #P              @ &I&P  :6YZ
B>2UE>#DY7S$N:'1M4$L%!@     #  , NP   $T_      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>inzy-20240312_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="inzy-20240312.xsd" xlink:type="simple"/>
    <context id="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2024-03-12</startDate>
            <endDate>2024-03-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_de32d52b-9853-49a4-8dfc-00bf5daa5e65">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_539c6662-430d-4c25-9a1f-7326fdd2b7b4">0001693011</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_7253656d-d5e8-4813-9a7f-56940d26f20d">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_57fe81a7-2787-4470-86f5-a1f04e0b4481">2024-03-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_ec5391f5-c0a2-41ae-b7e3-2e971a12ecfb">INOZYME PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_ecff7608-c46e-414a-a804-9b492d911436">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_2def2fed-7a2b-4d8c-be01-261f92fe58c6">001-39397</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_ecd61d28-aafc-454b-b070-320ba1c7b84c">38-4024528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_761f4538-c3ed-48a6-b03e-0c86f693e811">321 Summer Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_89973768-e40b-4854-9c09-33dc951d494f">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_6f890676-c8d6-4431-b4cd-3bb6ea920b73">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_ebce5d3d-ae3a-46e0-8c1a-b71852c7b3ad">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_f61d3cfe-4728-4d03-8c42-e27770b11212">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_749c6af5-95ef-4b37-b20b-2b06b4c826e5">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_49caf954-4546-406a-accd-51ad4c92c5fe">330-4340</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_910b0933-5db8-4d84-af3a-05d6ca244853">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_035ff59c-8c62-4177-a982-99f110f20113">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_f63437ec-9fa1-42b5-8486-61103741b2f1">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_3b09a367-1a69-4c69-8529-863b4193d938">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_de28fcb9-0497-47c9-9ff6-a092a0a31a72">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_5e04ae90-85d6-468d-ada3-6bc1151922c3">INZY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_90acb35a-5c0a-4670-94bf-cd15282cf619">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_004e6cb4-548d-4fad-97b8-c53dc99c9a77">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_7e4d20fa-113c-4ad9-a6d3-1e19b41f3301"
      id="F_058ce08a-57c9-4a04-ba73-5951654f993b">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
